World’s First Blood Type A-to-O Kidney Transplant Achieved by Avivo and UBC Researchers

Audio By Carbonatix

VANCOUVER, British Columbia--(BUSINESS WIRE)--Oct 6, 2025--

In a world-first, researchers have successfully transplanted a donor kidney after converting it from blood type A to the universal type O, removing one of the biggest barriers in organ donation: blood-type compatibility. The landmark study, published in Nature Biomedical Engineering, was led by Dr. Turun Song at West China Hospital in Chengdu, in partnership with the University of British Columbia (UBC) and Vancouver-based Avivo Biomedical Inc. (Avivo).

Transforming Transplant Medicine
More than 3,500 Canadians and 100,000 Americans await lifesaving organ transplants, yet many donor organs go unused due to blood-type mismatch. Researchers in this study used a proprietary enzyme system, discovered at UBC and being developed by Avivo, to convert a type A kidney to type O. The resulting Enzyme-Converted type-O (ECO) kidney was transplanted into a brain-dead, blood type–mismatched recipient using standard clinical protocols.

Key findings include:

• No hyperacute rejection was observed.
• The ECO kidney retained its physiological function post-transplant.

“This is the first time a type A human kidney has been converted to ECO and successfully transplanted into a mismatched recipient,” said John Coleman, CEO of Avivo. “Publication in Nature Biomedical Engineering underscores the significance of this breakthrough and its potential to transform organ transplantation. By enabling every donor organ to become universally compatible, our ECO platform has the potential to save more lives and reduce waitlist mortality.”

The Path to Universal Organ Access
The ability to convert donor kidneys – and ultimately other organs – into type O could dramatically expand the donor pool, reduce waitlist mortality, and ensure more equitable access to lifesaving transplants.

The decedent transplant model used in this study is particularly compelling, as it replicates real transplant conditions, including blood flow, immune response, and surgical handling, without exposing living patients to risk. Originally pioneered for xenotransplantation, the decedent model is recognized by the FDA as a pathway towards clinical trials. With these results, Avivo plans additional studies to evaluate longer-term graft survival.

From UBC Discovery to Global Impact
What began as basic science at UBC has now reached a global milestone.

“This discovery represents the culmination of over a decade of foundational science at UBC and shows how university spin-out companies like Avivo can bring transformative research to patients worldwide,” said Professor Jayachandran Kizhakkedathu, Department of Pathology and Lab Medicine & Center for Blood Research at UBC, and a senior investigator on the study.

About Avivo Biomedical Inc.
Avivo is a Vancouver-based preclinical company with a bold vision: a world where blood-type matching is no longer a barrier to lifesaving transplants or transfusions. Born out of UBC discovery, Avivo’s enzyme platform converts blood and organs into universally compatible type O – expanding availability, reducing waste, and enhancing equity. The company is advancing ECO organs toward first-in-human clinical trials.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251006694316/en/

CONTACT: Media Contact:

Avivo Biomedical Inc.

John Coleman, CEO

Email:[email protected]

Website:www.avivobio.com

KEYWORD: CHINA UNITED STATES UNITED KINGDOM CANADA NORTH AMERICA ASIA PACIFIC EUROPE

INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH SURGERY GENERAL HEALTH HEALTH CLINICAL TRIALS

SOURCE: Avivo Biomedical Inc.

Copyright Business Wire 2025.

PUB: 10/06/2025 08:30 AM/DISC: 10/06/2025 08:29 AM

http://www.businesswire.com/news/home/20251006694316/en